Caladrius Announces Research Collaboration
NeoSterm Name Changes to "Caladrius"
Announces Research Collaboration with the
University of Southern California
and California Institute of Technology

Collaboration will explore next-generation strategies for Caladrius' core cancer technology
New York, NY (June 22, 2015) - Caladrius Biosciences, Inc. (NASDAQ:CLBS), ("Caladrius" or the "Company", formerly NeoStem, Inc.), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today that it has entered into a material transfer agreement with the University of Southern California and the California Institute of Technology, concerning next-generation strategies for its core cancer technology.
This research collaboration will build on Caladrius' highly successful manufacturing protocol for its lead cancer program, CLBS20 (aka NBS20), by exploring techniques to further enhance the isolation of cancer initiating cells with the goal of increasing the number of cancer patients that might benefit from treatment.  
CLBS20 is the subject of a Phase 3 clinical trial investigating its efficacy in the treatment of late-stage melanoma, the Intus Study.  The trial has been granted a Special Protocol Assessment by the US Food and Drug Administration (FDA) and the CLBS20 development program has been granted Orphan Drug and Fast Track designations by FDA.  Randomization of the first patient in the Intus trial occurred in April 2015. 
"This collaboration illustrates Caladrius' continued commitment to the optimization of our technologies through association with two prominent research universities," said Dr. David J. Mazzo, Caladrius' Chief Executive Officer.  

Advanced melanoma is exceedingly difficult to treat, with a five-year survival rate of approximately 15%. There are 20,000 estimated new cases, and an estimated 10,000 deaths, from metastatic melanoma each year in the United States. The US melanoma market is approximately $1 billion per year, which is predominantly spent to treat metastatic melanoma. The platform on which CLBS20 is based is potentially applicable across multiple solid tumor types, including lung, colon and ovarian cancer, hepatocellular carcinoma and glioblastoma multiforme.

CLBS20 uses the patient's own immune cells and tumor-initiating cells to create an immunotherapy therapeutic vaccine. It is unique in targeting these cancer- or tumor-initiating cells; other therapies, which target different tumor cells, may treat existing cancer but may not be as likely to prevent tumor recurrence.
For more information on the Intus Study, which will be enrolling at approximately 50 sites across the US, Canada, Australia and New Zealand, please visit or

About Caladrius Biosciences, Inc. (formerly NeoStem, Inc.)
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.  
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-Oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.

Calidrius/NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Please visit our new service We would appreciate if you could pass our newsletter on to your friends and colleagues and naturally, we always appreciate your feedback and comments.
About SWI
SWI is a leading edge PR, Information Marketing and Research firm with a highly frequented web site, its "Rise Above The Noise" newsletter and SWI Research site These services provide readers with information and research on new and promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analyst reports and opinions from credible Wall Street firms that we respect and frequently sample. The weekly SWI QuickPicks  Ratings Report keeps you informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any of these stocks.  You can conveniently follow the live links for each of these stocks on for more detail.  SWI's periodical "Portfolio Performance Report" frequently reports about the performance of the stocks that we have purchased and may be trading in the SWI portfolio. Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site  
Google +
Good luck and please pass this newsletter on to a friend
to continue building our community.

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.

Copyright © 2015 DynamicMarketConcepts, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp